Is platelet activating factor (PAF) a mediator of endotoxin shock?

To determine whether endogenous PAF contributes to the pathogenesis of endotoxin shock, CV-3988, a specific PAF antagonist, was injected i.v. to rats before, simultaneously with or after endotoxin. CV-3988 (5 mg/kg i.v.) injected 5 min before the endotoxin completely inhibited endotoxin (15 mg/kg i....

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of pharmacology Vol. 109; no. 2; p. 257
Main Authors Terashita, Z, Imura, Y, Nishikawa, K, Sumida, S
Format Journal Article
LanguageEnglish
Published Netherlands 26.02.1985
Subjects
Animals
Blood Pressure - drug effects
Endotoxins - toxicity
Male
Phospholipid Ethers
Platelet Activating Factor - physiology
Rats
Rats, Inbred Strains
Shock, Septic - physiopathology
Thiazoles - pharmacology
Online AccessGet more information

Cover

More Information
Summary:To determine whether endogenous PAF contributes to the pathogenesis of endotoxin shock, CV-3988, a specific PAF antagonist, was injected i.v. to rats before, simultaneously with or after endotoxin. CV-3988 (5 mg/kg i.v.) injected 5 min before the endotoxin completely inhibited endotoxin (15 mg/kg i.v.)-induced hypotension, and CV-3988 (0.05-1 mg/kg i.v.) injected 7-10 min after the endotoxin rapidly reversed endotoxin-induced hypotension. A combination of CV-3988 (10 mg/kg) with endotoxin (5 mg/kg) administered i.v. improved the survival rate for 20 h or more. CV-3988 (0.05-1 mg/kg i.v.) rapidly reversed the PAF (1 microgram/kg i.v.)-induced hypotension. These findings strongly suggest that endogenous PAF may play a pivotal role in the pathogenesis of endotoxin shock.
ISSN:0014-2999
1879-0712
DOI:10.1016/0014-2999(85)90427-3